Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06237335 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06237335 · ClinicalTrials.gov record · last posted 2026-08-19

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

Name: A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF — clinical trial record (NCT06237335)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorReCode Therapeutics

Started2024-02-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.

Protocol amendment history 4 changes detected by DataLookout

2026-08-20

Enrollment closed, study ongoing

2026-08-20

Enrollment reduced: 192 → 128 participants

2026-08-20

Primary completion pushed: 2026-08-30 → 2026-11

2026-08-20

Completion moved earlier: 2026-12-31 → 2026-11

Trial Details

NCT Number	NCT06237335
Lead Sponsor	ReCode Therapeutics
Conditions	Cystic Fibrosis
Enrollment	128 participants
Start Date	2024-02-01
Primary Completion	2026-11 (estimated)
Study Completion	2026-11 (estimated)
Updated on ClinicalTrials.gov	2026-08-19